Home » SG biotech firm Mirxes reports 70% revenue drop in FY 2022, prospectus revealsSG biotech firm Mirxes reports 70% revenue drop in FY 2022, prospectus reveals August 5, 2023 All No CommentsThe company wants to develop a “super app” for precision multi-omics testing in Southeast Asia…Read More Tweet Pin It Related PostsFour Biotech Stocks for Parkinson’s Disease Awareness Month Biotech news from around the world Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast AsiaAbout The Author Cheapest Gadget
Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast Asia